Physician profile
Lawrence E Dasch
NPI 1700845716
$1,118.28
in general payments reported to CMS, 2019-2025
12 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.15 · 2020: $14.13 · 2021: $103 · 2022: $142 · 2023: $337 · 2024: $225 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $260.66 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $212.65 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $158.49 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $144.50 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $86.58 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $64.83 | 2023-2025 | Qulipta |
| Glaxosmithkline, LLC. | $59.23 | 2023-2024 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $45.58 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $44.14 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.41 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Dasch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.